Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected] Learn more

pBabe EGFR insertionH Citations (2)

Originally described in: Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors.
Yuza Y, Glatt KA, Jiang J, Greulich H, Minami Y, Woo MS, Shimamura T, Shapiro G, Lee JC, Ji H, Feng W, Chen TH, Yanagisawa H, Wong KK, Meyerson M Cancer Biol Ther. 2007 May . 6(5):661-7.
PubMed Journal

Articles Citing pBabe EGFR insertionH

Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations. Lee Y, Kim TM, Kim DW, Kim S, Kim M, Keam B, Ku JL, Heo DS. J Thorac Oncol. 2019 May 17. pii: S1556-0864(19)30369-7. doi: 10.1016/j.jtho.2019.05.006. PubMed
FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatment. Song X, Tang W, Peng H, Qi X, Li J. Invest New Drugs. 2021 Oct;39(5):1201-1212. doi: 10.1007/s10637-021-01061-1. Epub 2021 Apr 7. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.